Peer-reviewed veterinary case report
Liposomal cannabidiol injection for pain relief in dogs
By Shilo-Benjamini, Yael et al.·Published in Frontiers in veterinary science·2023·Department of Biochemistry·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis.
- Species:
- dog
Plain-English summary
A group of dogs with osteoarthritis received a single injection of liposomal-cannabidiol (CBD) to help manage their pain. Over six weeks, the dogs showed significant improvements in activity levels and reduced pain scores, with owners reporting better overall wellbeing. The most common side effect was minor swelling at the injection site, which resolved quickly. This treatment appears to be a promising option for dogs suffering from chronic joint pain, especially when traditional pain medications aren't effective.
People also search for: dog osteoarthritis treatment · CBD for dogs pain relief · dog joint pain injection · liposomal CBD for dogs · dog arthritis management
Abstract
INTRODUCTION: Osteoarthritis is a common disease in dogs resulting in chronic pain and decreased wellbeing. Common analgesics such as non-steroidal anti-inflammatories may fail to control pain and can produce major adverse effects. Study objectives were to evaluate pharmacokinetics, therapeutic efficacy, and safety of subcutaneous liposomal-cannabidiol (CBD) as an additional analgesic therapy in dogs suffering from naturally-occurring osteoarthritis. METHODS: Six such dogs were recruited following ethics approval and owner consent. Dogs were administered a single subcutaneous injection of 5 mg/kg liposomal-CBD. Plasma concentrations of CBD, blood work, activity monitoring collar data, wellbeing questionnaire (owners) and pain scoring (veterinarian) were performed at baseline and monitored up to six weeks following intervention. Data overtime were compared with baseline using linear-regression mixed-effects.-value was set at 0.05. RESULTS: CBD plasma concentrations were observed for 6 weeks; median (range) peak plasma concentration (C) was 45.2 (17.8-72.5) ng/mL, time to Cwas 4 (2-14) days and half-life was 12.4 (7.7-42.6) days. Median (range) collar activity score was significantly increased on weeks 5-6; from 29 (17-34) to 34 (21-38). Scores of wellbeing and pain evaluations were significantly improved at 2-3 weeks; from 69 (52-78) to 53.5 (41-68), and from 7.5 (6-8) to 5.5 (5-7), respectively. The main adverse effect was minor local swelling for several days in 5/6 dogs. CONCLUSION: Liposomal-CBD administered subcutaneously produced detectable CBD plasma concentrations for 6 weeks with minimal side effects and demonstrated reduced pain and increased wellbeing as part of multimodal pain management in dogs suffering from osteoarthritis. Further placebo-controlled studies are of interest.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37680386/